Self-reactive antibodies that cause most cases of neuromyelitis optica spectrum disorder (NMOSD) are released directly from immune B-cells in…
Articles by Steve Bryson, PhD
Uplizna (inebilizumab-cdon) was just as safe and effective in people with neuromyelitis optica spectrum disorder (NMOSD) treated after…
Uplizna (inebilizumab-cdon) effectively reduced the severity of attacks in people with neuromyelitis optica spectrum disorder (NMOSD) who continued…
People with neuromyelitis optica spectrum disorder (NMOSD) experience a high prevalence of co-existing conditions, or comorbidities, which are associated…
Uplizna (inebilizumab-cdon) safely prevented autoimmune attacks in 83% of people with neuromyelitis optica spectrum disorder (NMOSD) who received…
Almost half of U.S. patients with neuromyelitis optica spectrum disorder (NMOSD) experienced relapses over a period of two years,…
Enspryng (satralizumab), a therapy for adolescents and adults with neuromyelitis optica spectrum…
The autoimmune biomarker CH50 was directly impacted by treatment with Soliris (eculizumab) in three…
Enspryng has been approved by the Taiwan Food and Drug Administration for treating people 12…